Bottom line
How much do LHCOX and HRTS overlap?
49% of their top holdings overlap by weight. 11 securities appear in both funds' top 25, making up 40.3% of LHCOX's assets and 45.7% of HRTS's. They share a meaningful core but differ in the rest of the portfolio.
Updated Nov 22, 2026
Overlap at a glance
Holdings LHCOX and HRTS have in common
| Holding | % of LHCOX | % of HRTS | Overlap |
|---|---|---|---|
| Eli Lilly & Co | 10.40% | 11.52% | 10.40% |
| UnitedHealth Group Inc | 5.39% | 5.24% | 5.24% |
| Johnson & Johnson | 4.96% | 3.59% | 3.59% |
| Novartis AG | 4.19% | 3.38% | 3.38% |
| Gilead Sciences Inc | 3.53% | 3.43% | 3.43% |
| Thermo Fisher Scientific Inc | 2.31% | 3.97% | 2.31% |
| Vertex Pharmaceuticals Inc | 2.24% | 2.93% | 2.24% |
| AstraZeneca PLC | 1.97% | 4.00% | 1.97% |
| Bridgebio Pharma Inc | 1.84% | 2.59% | 1.84% |
| Edwards Lifesciences Corp | 1.78% | 1.75% | 1.75% |
| Revolution Medicines Inc | 1.67% | 3.33% | 1.67% |
Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)
Free weekly newsletter
The Fund Letter
Get fee cuts and hikes, fund closures and mergers, and one plain-English idea to make your portfolio cheaper — every week.
Free. Unsubscribe anytime. We never sell your email.
What each fund holds that the other doesn't
Top-25 holdings that appear in only one of the two funds' top 25.
Only in LHCOX
- Natera Inc — 3.60%
- CVS Health Corp — 3.33%
- Guardant Health Inc — 2.61%
- Galderma Group AG — 2.60%
- Cogent Biosciences Inc — 2.27%
- 10X Genomics Inc — 2.16%
- BeOne Medicines Ltd — 2.06%
- Ascendis Pharma A/S — 1.99%
- Madrigal Pharmaceuticals Inc — 1.91%
- Arrowhead Pharmaceuticals Inc — 1.52%
- Protagonist Therapeutics Inc — 1.44%
- Dianthus Therapeutics Inc — 1.44%
- Adaptive Biotechnologies Corp — 1.42%
- Illumina Inc — 1.42%
Only in HRTS
- Novo Nordisk A/S — 5.24%
- Roche Holding AG — 4.50%
- Merck & Co Inc — 4.27%
- Danaher Corp — 2.66%
- Abbott Laboratories — 2.61%
- Cytokinetics Inc — 2.52%
- AbbVie Inc — 2.40%
- Bristol-Myers Squibb Co — 2.09%
- Teva Pharmaceutical Industries — 2.06%
- Dexcom Inc — 1.92%
- Amgen Inc — 1.91%
- Medtronic PLC — 1.88%
- McKesson Corp — 1.71%
- Regeneron Pharmaceuticals Inc — 1.67%
Asset mix
| Asset type | LHCOX | HRTS |
|---|---|---|
| Stocks | 98.2% | 99.2% |
| Repurchase agreements | 1.2% | — |
| Cash & short-term funds | 0.8% | 0.7% |
Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)
Country mix
| Country | LHCOX | HRTS |
|---|---|---|
| US | 78.5% | 74.9% |
| CH | 8.8% | 7.9% |
| DK | 2.0% | 7.0% |
| GB | 2.0% | 4.0% |
| NL | 2.2% | — |
| IL | 1.2% | 2.1% |
| IE | — | 1.9% |
| BE | 1.4% | — |
Source: SEC Form N-PORT (periods Jul 31, 2026 / May 31, 2026)
Check another pair
FAQ
How much do LHCOX and HRTS overlap?
What stocks do LHCOX and HRTS have in common?
Should I own both LHCOX and HRTS?
Which holds more stocks, LHCOX or HRTS?
Overlap is computed from each fund's top 25 holdings in its latest SEC Form N-PORT filing, with weights normalized to the top 25; for each shared security we count the smaller of the two weights. Educational information, not investment advice.